Exact Sciences (EXAS) reported a Q3 loss late Tuesday of $0.21 per diluted share, compared with breakeven a year earlier.
Analysts polled by Capital IQ expected a loss of $0.18.
Revenue for the quarter that ended Sept. 30 was $708.7 million, up from $628.3 million a year earlier.
Analysts surveyed by Capital IQ expected $717 million.
The company expects full-year 2024 revenue of $2.73 billion to $2.75 billion, compared with its prior projections of $2.81 billion to $2.85 billion. Analysts polled by Capital IQ expect $2.83 billion.
Shares of Exact Sciences traded 28% lower in after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。